Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,980.00
-50.00 (-0.62%)
Mar 20, 2026, 3:30 PM KST
Market Cap185.59B -13.4%
Revenue (ttm)n/a +13,737.3%
Net Incomen/a
EPSn/a
Shares Out23.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume121,662
Average Volume205,173
Open8,030.00
Previous Close8,030.00
Day's Range7,980.00 - 8,210.00
52-Week Range6,970.00 - 12,670.00
Beta0.89
RSI38.76
Earnings DateNov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements